Article Text

Download PDFPDF
Review: postmenopausal oestrogen replacement therapy increases the risk for venous thromboembolism

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


 
 QUESTION: In postmenopausal women receiving hormone replacement therapy (HRT), what is the risk for venous thromboembolism (VTE)?

Data sources

Studies were identified by searching Medline (1966 to 2000), HealthSTAR (1975 to 2000), and the Cochrane Controlled Trials Register, and by scanning the bibliographies of relevant studies and reviews.

Study selection

Studies were selected if they were published in English or had English-language abstracts, enrolled postmenopausal women, and reported deep venous thrombosis, pulmonary embolism, or VTE as adverse events related to oestrogen use. Studies that selected participants on the basis of previous thromboembolic events or risk for thrombosis were excluded.

Data extraction

Data were extracted on participants, treatment (for randomised controlled trials [RCTs]), definition and method for determining exposure (for case control and cohort studies), event rates, confounders, outcome measurement, and study duration. 2 reviewers independently rated study quality.

Main results

12 trials were included: 3 RCTs, 8 case control studies, and 1 cohort study. Risk for …

View Full Text

Footnotes

  • Sources of funding: Agency for Healthcare Research and Quality; Portland Veterans Affairs Medical Center Women’s Health Fellowship.

  • For correspondence: Dr J Miller, Oregon Health and Science University, Portland, Oregon, USA. millerji{at}ohsu.edu.